Animal models of human type 1 diabetes for evaluating combination therapies and successful translation to the patient with type 1 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 33, Issue 7, 2017, Pages

  Lenzen, Sigurd ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

animal models of human type 1 diabetes; prevention therapies; type 1 diabetes mellitus

Indexed keywords

ANIMAL MODEL; CLINICAL EVALUATION; DIABETIC PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE MODEL; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; RAT MODEL; REVIEW; THERAPY; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; ANIMAL; COMBINATION DRUG THERAPY; DISEASE MODEL; MOUSE; RAT;

ANTIDIABETIC AGENT;

ANIMALS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; MICE; RATS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85026664313     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2915     Document Type: Review

References (35)

1. Freedman LP, Cockburn IM, Simcoe TS. The economics of reproducibility in preclinical research. PLoS Biol. 2015;13:e1002165.
2. Atkinson MA. Evaluating preclinical efficacy. Sci Transl Med. 2011;3:96cm22.
3. King AJF. The use of animal models in diabetes research. Br J Pharmacol. 2012;166:877-894.
4. Al-Awar A, Kupai K, Veszelka M, et al. Experimental diabetes mellitus in different animal models. J Diabetes Res. 2016;2016:9051426.
5. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu. 1980;29:1-13.
6. Ben Nasr M, D'Addio F, Usuelli V, Tezza S, Abdi R, Fiorina P. The rise, fall, and resurgence of immunotherapy in type 1 diabetes. Pharmacol Res. 2015;98:31-38.
7. Roep BO. Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth. Ann N Y Acad Sci. 2007;1103:1-10.
8. Rossini AA, Handler ES, Mordes JP, Greiner DL. Human autoimmune diabetes mellitus: lessons from BB rats and NOD mice—caveat emptor. Clin Immunol Immunopathol. 1995;74:2-9.
9. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med. 1999;5:601-604.
10. Greiner DL, Rossini AA, Mordes JP. Translating data from animal models into methods for preventing human autoimmune diabetes mellitus: caveat emptor and primum non nocere. Clin Immunol. 2001;100:134-143.
11. Roep BO, Atkinson M. Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal. Diabetologia. 2004;47:1650-1656.
12. Jörns A, Arndt T, Meyer zu Vilsendorf A, et al. Islet infiltration, cytokine expression and beta cell death in the NOD mouse, BB rat, Komeda rat, LEW.1AR1-iddm rat and humans with type 1 diabetes. Diabetologia. 2014;57:512-521.
13. Xue S, Posgai A, Wasserfall C, et al. Combination therapy reverses hyperglycemia in NOD mice with established type 1 diabetes. Diabetes. 2015;64:3873-3884.
14. Mehta DS, Christmas RA, Waldmann H, Rosenzweig M. Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice. Immunology. 2010;130:103-113.
15. Hagopian W, Ferry RJ Jr, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes. 2013;62:3901-3908.
16. Aronson R, Gottlieb PA, Christiansen JS, et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014;37:2746-2754.
17. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M, et al. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol. 2010;160:176-184.
18. Boettler T, von Herrath M. Immunotherapy of type 1 diabetes—how to rationally prioritize combination therapies in T1D. Int Immunopharmacol. 2010;10:1491-1495.
19. Ludvigsson J. Combination therapy for preservation of beta cell function in type 1 diabetes: new attitudes and strategies are needed! Immunol Lett. 2014;159:30-35.
20. Pozzilli P, Maddaloni E, Buzzetti R. Combination immunotherapies for type 1 diabetes mellitus. Nat Rev Endocrinol. 2015;11:289-297.
21. Nakhooda AF, Like AA, Chappel CI, Murray FT, Marliss EB. The spontaneously diabetic Wistar rat. Metabolic and morphologic studies. Diabetes. 1977;26:100-112.
22. Mordes JP, Bortell R, Blankenhorn EP, Rossini AA, Greiner DL. Rat models of type 1 diabetes: genetics, environment, and autoimmunity. ILAR J. 2004;45:278-291.
23. Wang GS, Kauri LM, Patrick C, Bareggi M, Rosenberg L, Scott FW. Enhanced islet expansion by beta-cell proliferation in young diabetes-prone rats fed a protective diet. J Cell Physiol. 2010;224:501-508.
24. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. New inbred strain of Long-Evans Tokushima lean rats with IDDM without lymphopenia. Diabetes. 1991;40:1375-1381.
25. Komeda K, Noda M, Terao K, Kuzuya N, Kanazawa M, Kanazawa Y. Establishment of two substrains, diabetes-prone and non-diabetic, from long-Evans Tokushima Lean (LETL) rats. Endocr J. 1998;45:737-744.
26. Lenzen S, Tiedge M, Elsner M, et al. The LEW.1AR1/Ztm-iddm rat: a new model of spontaneous insulin-dependent diabetes mellitus. Diabetologia. 2001;44:1189-1196.
27. Jörns A, Günther A, Hedrich HJ, Wedekind D, Tiedge M, Lenzen S. Immune cell infiltration, cytokine expression, and beta-cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW.1AR1/Ztm-iddm rat. Diabetes. 2005;54:2041-2052.
28. Arndt T, Jörns A, Weiss H, et al. A variable CD3(+) T-cell frequency in peripheral blood lymphocytes associated with type 1 diabetes mellitus development in the LEW.1AR1-iddm rat. PLoS One. 2013;8:e64305.
29. Yokoi N, Komeda K, Wang HY, et al. Cblb is a major susceptibility gene for rat type 1 diabetes mellitus. Nat Genet. 2002;31:391-394.
30. MacMurray AJ, Moralejo DH, Kwitek AE, et al. Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene. Genome Res. 2002;12:1029-1039.
31. Arndt T, Wedekind D, Jörns A, et al. A novel Dock8 gene mutation confers diabetogenic susceptibility in the LEW.1AR1/Ztm-iddm rat, an animal model of human type 1 diabetes. Diabetologia. 2015;58:2800-2809.
32. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010;53:614-623.
33. Jörns A, Ertekin UG, Arndt T, Terbish T, Wedekind D, Lenzen S. TNF-alpha antibody therapy in combination with the T-cell-cpecific antibody anti-TCR reverses the diabetic metabolic state in the LEW.1AR1-iddm rat. Diabetes. 2015;64:2880-2891.
34. Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care. 2015;38:989-996.
35. Jörns A, Akin M, Arndt T, et al. Anti-TCR therapy combined with fingolimod for reversal of diabetic hyperglycemia by beta cell regeneration in the LEW.1AR1-iddm rat model of type 1 diabetes. J Mol Med (Berl). 2014;92:743-755.